DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Stamulumab
Stamulumab
The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
The Two Tontti Tudiul Lui Hi Ha Unit
WHO Drug Information Vol. 20, No. 3, 2006
Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy
Novel Myostatin-Specific Antibody Enhances Muscle Strength In
INN Working Document 05.179 Update 2011
Therapeutic Antibody
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Prohibited List 2021
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Receptor-Mediated Muscle Homeostasis As a Target for Sarcopenia Therapeutics
Crossfit Games Drug Testing Policy Aims to Prevent the Use of Prohibited Substances Through Rigorous Testing
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Top View
International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
Targeting Myostatin Signaling in Skin Healing
Assessment of the Evolution of Cancer Treatment Therapies
School of Pharmacy Personal Statement.Pdf
Current Status of Drug Development for Sarcopenia
Immunotherapy – a Novel Facet of Modern Therapeutics Immunotherapy – a Novel Facet of Modern Therapeutics Sujata P
Com(2010)0397
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Engineered Fc Regions for Site-Specific Conjugation
PFIZER INC. These Results Are Supplied for Informational Purposes
Blocking Extracellular Activation of Myostatin As a Strategy for Treating Muscle Wasting Received: 4 October 2017 M
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
2020 Prohibited List
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Assessment of the Evolution of Cancer Treatment Therapies
Myostatin Inhibitors: Panacea Or Predicament for Musculoskeletal Disorders?
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT